It seems some commentators in the broader market have also forgotten that the trial is at the stage of testing safety not efficacy. Whether it works or not is not even part of the parameter at this point, that comes next. So the fact that patients responded to previously redundant treatments is quite significant.
It seems some commentators in the broader market have also...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
